Cadrenal Therapeutics Launches Partnering Process After Strong CAD-1005 Data
Event summary
- Cadrenal Therapeutics reported a net loss of $3.3 million for Q2 2026, down from $3.7 million in Q2 2025.
- Presented late-breaking Phase 2 data on CAD-1005 at ISTH 2026 Congress, showing >25% reduction in thrombotic events.
- Launched structured partnering process for CAD-1005, frunexian, and tecarfarin to explore development and commercialization transactions.
- Submitted request for Rare Pediatric Disease Designation for tecarfarin in Kawasaki Disease prevention.
The big picture
Cadrenal Therapeutics is positioning itself for strategic partnerships following positive Phase 2 data for CAD-1005. The company aims to monetize its Cardiac Acute Critical Care Franchise through out-licensing and co-development agreements, addressing high-value needs across the cardiac surgery continuum. With limited cash reserves expected to last until Q1 2027, securing non-dilutive funding will be critical for advancing its pipeline.
What we're watching
- Partnering Strategy
- Whether Cadrenal can secure non-dilutive funding through strategic partnerships to advance its pipeline.
- Regulatory Progress
- The pace at which CAD-1005 and tecarfarin receive further regulatory designations and approvals.
- Financial Sustainability
- How long Cadrenal's current cash reserves will last and the likelihood of additional funding rounds.